Amylyx Pharmaceuticals, Inc. (AMLX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
AMLX currently has 111M outstanding shares. with limited dilution risk as only 17M additional shares (15.3%) are authorized for issuance. The company has significantly diluted shareholders by 59.05% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 110.6M shares outstanding |
110M | 17M |
| Nov 06, 2025 |
10-Q filing | 109.8M shares outstanding |
110M | 17M |
| May 08, 2025 |
10-Q filing | 85.7M shares outstanding |
86M | 17M |
| Mar 04, 2025 |
10-K filing | 88.6M shares outstanding |
89M | 17M |
| Mar 04, 2025 |
S-3 filing: The company may offer up to $300,000,000 in the aggregate principal amount of common stock, preferred stock, debt securities, warrants, and units. |
68M | 17M |
| Nov 07, 2024 |
10-Q filing | 68.1M shares outstanding |
68M | 17M |
| Aug 08, 2024 |
10-Q filing | 68.0M shares outstanding |
68M | 17M |
| May 09, 2024 |
10-Q filing | 67.9M shares outstanding |
68M | 17M |
| Feb 22, 2024 |
10-K filing | 67.2M shares outstanding |
67M | 17M |
| Nov 09, 2023 |
10-Q filing | 67.4M shares outstanding |
67M | 17M |
| Aug 10, 2023 |
10-Q filing | 67.2M shares outstanding |
67M | 17M |
| May 11, 2023 |
10-Q filing | 66.7M shares outstanding |
67M | 17M |
| Mar 13, 2023 |
10-K filing | 66.7M shares outstanding |
67M | 17M |
| Nov 10, 2022 |
10-Q filing | 66.3M shares outstanding |
66M | 17M |
| Oct 04, 2022 |
S-1 filing: The company is offering 6,000,000 shares of its common stock in an S-1 filing, with the last reported sale price on October 3, 2022, at $29.75 per share, and granting underwriters a 30-day option to purchase up to 900,000 additional shares. |
65M | 17M |
| Aug 11, 2022 |
10-Q filing | 58.3M shares outstanding |
58M | 10M |
| May 12, 2022 |
10-Q filing | 58.5M shares outstanding |
59M | 10M |
| Jan 03, 2022 |
S-1/A filing: This S-1/A filing relates to an offering of common stock with an option to purchase additional shares. The company intends to use the net proceeds from this offering to fund regulatory approval processes, clinical trials, and pipeline development, as well as for working capital and general corporate activities. |
7M | 10M |
| Dec 16, 2021 |
S-1 filing: This S-1 filing includes information on a common stock offering, an option to purchase additional shares, and the number of common stock to be outstanding immediately following the offering. |
46M | 0 |